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New guidelines for LF with the intro-
duction of triple drug therapy using a
combination of ivermectin, diethylcar-
bamazine, and albendazole (IDA).
New guidelines for the new onchocer-
ciasis ‘elimination’ goal.
Development of POCT diagnostics for
all three ﬁlarial infections.
New ‘test and not treat’ (TaNT) strat-
egy for Loa loa.
New community-based morbidity
mapping methods for LF.Lymphatic ﬁlariasis (LF) and onchocerciasis are two neglected tropical dis-
eases (NTDs) of public health signiﬁcance targeted for global elimination. The
World Health Organization (WHO) African Region is a priority region, with the
highest collective burden of LF and onchocerciasis globally. Coendemic
loiasis further complicates elimination due to the risk of adverse events
associated with ivermectin treatment. A public health framework focusing
on health-related data, systematic collection of data, and analysis and inter-
pretation of data is used to highlight the range of innovative surveillance
strategies required for ﬁlariasis elimination. The most recent and signiﬁcant
developments include: rapid point-of-care test (POCT) diagnostics; clinical
assessment tools; new WHO guidelines; open-access online data portals;
mHealth platforms; large-scale prevalence maps; and the optimisation of
mathematical models.New tools for measuring lymphoe-
dema and impact of interventions.
Online NTD portals – repositories
increasing data availability and
connectivity.
mHealth tools to enable electronic
capture and connectivity of ﬁeld data.
Continental prevalence maps to deter-
mine populations at risk.
Mathematical models to help deter-
mine critical transmission reduction
thresholds and time-bound eliminationA Public Health Surveillance Framework for Filariasis in Africa
The African Context
LF and onchocerciasis are two vector-borne neglected tropical diseases (NTDs) (see Glos-
sary) of public health signiﬁcance currently targeted for global elimination [1]. The ﬁlarial nematode
Wuchereria bancrofti, transmitted by mosquitoes predominantly of Anopheles and Culex spp., is
responsible for 90% of the global infection and the clinical manifestations of LF, which include limb
lymphoedema, genital disease such as hydrocoele and chylocele, and acute dermatolymphan-
gioadenitis (ADLA) [2]. Onchocerca volvulus, a ﬁlarial worm transmitted by black ﬂies of the genus
Simulium, is the causative agent of onchocerciasis and clinical manifestations of the disease,
which include blindness, visual impairment, and intensely pruritic skin lesions [2]. Heavy infection
with O. volvulus has been associated with an increased risk of death over and above that
associated with blindness [3], particularly in children and young adults [4].endpoints.
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(L.A. Kelly-Hope).The main elimination strategy for both diseases aims to interrupt transmission through large-
scale community-based preventive chemotherapy programmes, which are implemented
through national NTD programmes in coordination with the WHO, and international pharma,
bilateral and philanthropic donors, research organizations and nongovernmental development
organisation (NGDO) partners [5,6]. Preventive chemotherapy for ﬁlariasis includes the donated
drugs ivermectin, diethylcarbamazine (DEC), and albendazole, administered in different com-
binations through community mass drug administration (MDA) campaigns. In recent
decades, there has been signiﬁcant scaling up of MDA, with widespread reductions in
transmission across many endemic countries. As national programmes progress towards
the endpoint, it is becoming increasingly important to monitor and document the changing
epidemiology, elimination successes and failures in order to reﬁne strategies and learn how
elimination is best achieved.694 Trends in Parasitology, August 2018, Vol. 34, No. 8 https://doi.org/10.1016/j.pt.2018.05.004
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Glossary
Community-directed treatment
with ivermectin (CDTI): a strategy
for mass drug administration of
ivermectin to communities for
onchocerciasis. Drug distribution is
directed by the community and
delivered by community drug
distributors (CDDs).
Enzyme-linked immunosorbent
assay (ELISA): a common
microplate-based technique used in
the laboratory to determine the
presence and abundance of
antibodies or antigens. The intensity
of colour that develops as an end-
product is measured and this
correlates to the amount of the
target present in the sample.
Loop-mediated isothermal
ampliﬁcation (LAMP): a method for
rapid ampliﬁcation of DNA or RNA
under isothermal conditions. This
method does not require a thermal
cycler, and is lower cost and more
suitable for point-of-care testing than
PCR.
Mass drug administration (MDA):
anthelmintic drugs are given to the
entire population at risk at regular
intervals, irrespective of the individual
infection status.
Microﬁlariae (mf): larvae released
from the adult female worms that are
taken up by the vector species,
enabling the infection to be
transmitted to a new host. Mf in the
peripheral blood (lymphatic ﬁlariasis
and loiasis) is referred to as
microﬁlaraemia, and mf in the skin
(onchocerciasis) is referred to as
microﬁlaridermia.
Mobile health (mHealth): use of
mobile devices, such as mobile
phones and other wireless devices,
to support medical and public health
practice. mHealth involves utilising
short messaging service (SMS) as
well as more advanced features and
functionalities, such as global
positioning system (GPS).
Neglected tropical diseases
(NTDs): a collective term
encompassing a diverse group of
(mostly) communicable diseases of
poverty (excluding malaria, HIV, and
TB), which was coined against the
backdrop of these ‘big three’ to raise
the proﬁle of, and unite efforts
against, tropical/subtropical
infections/conditions.The WHO African Region (AFRO) is a priority region with a planned accelerated MDA programme,
and increased funding and technical support provided through the new Expanded Special Project
for Elimination of NTDs (ESPEN) entity based in the WHO/AFRO Regional Ofﬁce, and a wide range
of international partners. The African region has the highest collective burden of ﬁlariasis, with over
500 million people requiring preventive chemotherapy for LF (371 m), and onchocerciasis (197 m)
in 2016, accounting for 43.3% and 99.5% of the global total, respectively [5]. Further, many
programmes are behind essential targets, and ten countries have the additional complication of
loiasis (tropicaleye worm),causedby infectionwith the ﬁlarialnematode Loa loa andtransmittedby
Tabanidae ﬂies of the Chrysops species in Central and West Africa [7]. The main clinical man-
ifestations of loiasis include subconjunctival migration of the adult worms (eye worm) and localised
skin angioedema (Calabar swelling) [8–10].
The wide distribution of loiasis remains a major barrier for LF and onchocerciasis programmes in
Central and West Africa, as ivermectin and DEC cannot readily be used in areas with high L. loa
prevalence due to the risk of severe adverse events (SAEs) in people with high microﬁlarial
(mf) densities [8,11,12]. Therefore, alternative intervention strategies are required for LF and
onchocerciasis programmes in loiasis coendemic areas, and understanding the extent of over-
lappingendemicitiesbetweenthethreeﬁlarial infections– andtheassociated risks and beneﬁts– is
crucial to implementing safe interventions and meeting the elimination goals set out by the WHO.
A Surveillance Framework
The African Region is ecologically complex and will require a unique suite of surveillance
strategies to help document the impact of interventions, track progress toward the elimination
goals, and to monitor and describe the changing epidemiology in order to set priorities and
inform public health policy and practice [13]. The WHO deﬁnes public health surveillance as ‘the
continuous, systematic collection, analysis and interpretation of health-related data needed for
the planning, implementation, and evaluation of public health practice’ (http://www.who.int/
topics/public_health_surveillance/en/). This deﬁnition is used as a framework to highlight that
surveillance is a dynamic cycle with key interlinked components (Figure 1), and to provide a
holistic overview of new strategies that are relevant to ﬁlariasis elimination in Africa, which are, or
have the potential to be, integrated into standard practice in the future.
Control and Elimination Programmes
The WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established in 2000 after
LFwas identiﬁedasoneofseveraldiseasesthatcouldbeeliminatedasapublichealthproblemthrough
safe and affordable drug regimens. Global elimination of LF is targeted for 2020 [14]. The GPELF is one
of the longest running NTD elimination programmes, and has two well-deﬁned goals and step-wise
phases: (i) interruptionof transmissionusingMDA,withsupplementaryvectorcontrol/integratedvector
management (VC/IVM), and (ii) alleviate suffering through morbidity management and disability
prevention (MMDP), shown in Figure 2A. The GPELF strategy provides a clear framework for national
LF elimination programmes to assist in reaching targets, which includes regular monitoring and
evaluation (M&E) and a post-MDA surveillance in endemic districts or implementation units (IUs).
In contrast to the GPELF, the goal of global onchocerciasis elimination is relatively new, and
evolved from decades of control efforts [15,16]. The ﬁrst programme, the Onchocerciasis
Control Programme (OCP), aimed to control the disease in West African countries, using vector
control (aerial larviciding), and later through a combination of vector control and ivermectin
treatment following the donation by Merck & Co. in 1987 [17,18]. The African Programme for
Onchocerciasis Control (APOC) was subsequently established to control onchocerciasis in
meso- to hyper-endemic areas in countries not covered by the OCP, through the then-newTrends in Parasitology, August 2018, Vol. 34, No. 8 695
Point-of-care tests (POCTs):
diagnostic tests that are designed to
be used outside of the laboratory at
or near the site of patient care.
Rapid diagnostic tests (RDTs): are
generally simple to perform and
interpret, provide results rapidly,
require limited training, and allow for
the diagnosis at the community level.
They may detect antigens of the
parasite or antibodies to the parasite.
Severe adverse event (SAE): an
untoward medical occurrence as a
result of treatment that results in
death; is life-threatening; requires
hospitalization; results in disability/
incapacity; or requires intervention to
prevent permanent impairment or
damage.
Skin snip: a small skin sample or
biopsy (1–2 mg) collected from
multiple sites (iliac crests, shoulder
blades) using a razor blade or skin
punch. Skin snips are immersed in
saline, and the emergence of
Onchocerca volvulus microﬁlariae is
diagnostic for onchocerciasis
infection.
Transmission assessment survey
(TAS): a study intended to determine
whether or not infection levels within
an evaluation unit have diminished to
an extent such that recrudescence of
infection is unlikely to occur, even in
the absence of continued
intervention efforts.
Xenomonitoring: testing the insect
vectors for the presence of parasites
to monitor the prevalence and
transmission potential within a
community.
Health
related
Systemac
collecon 
Analysis and
interpretaon
-     Sampling
-     Connecvity
-     Indicators
-     Diagnoscs
-     Mapping
-     Modelling
i)
ii)
iii)
Health-related data: measured using clinical, parasitological,
immunological and molecular indicators, and point-of-care test
and laboratory diagnosc tools
Systemac collecon of data: presented as standard guidelines
regarding sampling approaches, and data connecvity plaorms
Analysis and interpretaon of data: presented using mapping and
modelling techniques
Figure 1. Key Components of Public Health Surveillance.community-directed treatment with ivermectin (CDTI) strategy [19]. The achievements of
the OCP and APOC led to a shift in strategy from the control to the elimination of onchocercia-
sis, which now includes untreated hypo-endemic areas [20,21]. The ESPEN recently replaced
APOC, and promotes an integrated approach to eliminating onchocerciasis together with other
NTDs, including LF. The new strategy has three key phases to help achieve elimination
(Figure 2B) [21].
In contrast to LF and onchocerciasis, loiasis is not classiﬁed as an NTD by the WHO, and
consequently there are no formalised control or elimination strategies for the disease itself.
However, there is increasing recognition that more research is urgently needed to assess the
public health burden of L. loa in endemic communities [10,22–24]. In recent years infection has
also been associated with arthritis, cardiomyopathy, encephalopathy, lymphangitis, peripheral
neuropathy, retinopathy, and an increased risk of death [25], with animal models investigating
the pathogenesis of Loa-associated encephalopathy following ivermectin treatment [26].
Health-Related Data: Prevalence Indicators and Diagnostics
To meet the GPELF and onchocerciasis elimination targets, sensitive, speciﬁc, cost-effective
and ﬁeld-applicable diagnostics are required for all three ﬁlarial infections and may include a
range of clinical, parasitological, immunological, and molecular indicators and diagnostic tools
(Figure 3). Several reviews related to LF and onchocerciasis diagnostics have recently been
published [27–32], and those commercially developed and relevant to programmatic surveil-
lance are summarised below.
LF
The primary indicators and diagnostic tools for the different stages of the GPELF strategy include
parasitological identiﬁcation of mf in blood collected at night using thick smear microscopy [33]696 Trends in Parasitology, August 2018, Vol. 34, No. 8
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Figure 2. LF and Onchocerciasis Control and Elimination Frameworks. Also see [14].and ﬁlarial-antigen tests which detect adult W. bancrofti antigens in blood. The BinaxNOW1
Filariasis immunochromatographic card test (ICT) was introduced in the late 1990s as the ﬁrst
rapid antigen test detecting W. bancrofti circulating ﬁlarial antigen (CFA), using an antiﬁlarial
monoclonal antibody (AD12.1) [34], and has since been used extensively for national endemicity
mapping. This-easy-to-use point-of-care test (POCT) is more sensitive than mf microscopy
and can be used at any time of the day. In recent years, there has been an increased use of POCTs
forMDA impact and endpoint assessments,which is largelydueto the increase in donor funding to
support procurement. The main limitation of the ICT is that it can result in false positives, as the ICT
has been shown to be cross-reactive in people with high L. loa mf densities [35–38]; alternative
tools are therefore required to measure LF in loiasis coendemic areas. Other secondary LF
diagnostic tools available include the TropBio Og4C3 Ag enzyme-linked immunosorbent
assay (ELISA) to detect W. bancrofti CFA using the monoclonal antibody Og4C3 (a new version
of the kit, ‘Tropbio Filariasis Antigen II’ was released in 2014), antibody testing in blood and urine
[39], and polymerase chain reaction (PCR)/quantitative PCR (qPCR) for detection of W. bancrofti-
speciﬁc DNA both in blood and in mosquitoes for xenomonitoring [40]. However, they are not
routinely used and/or included in WHO guidelines for LF [27,28].
What’s New in Diagnostic Tests
The most recent and signiﬁcant developments for the transmission of W. bancrofti include the
further development of the W. bancrofti BinaxNOW1 Filariasis ICT, known as the Alere Filariasis
Test Strips (FTS). The new FTS is increasingly being used in all steps of the GPELF strategy as it
is lower in cost, has increased stability, and is considered to be more sensitive and stringent for
surveillance [41–43]. However, it has the same limitations as the ICT in LF-loiasis coendemic
areas. Other diagnostic developments for LF include an antibody-based ELISA, the InbiosTrends in Parasitology, August 2018, Vol. 34, No. 8 697
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Figure 3. Tabulated Summary of Lymphatic Filariasis, Onchocerciasis, and Loiasis Diagnostics.
aDiagnostic tests for bancroftian lymphatic ﬁlariasis (caused by infection with W. bancrofti) only are discussed here.
bThere are currently no commercial tests available for programmatic use. Antigen-detection tests so far have not had the necessary sensitivity or speciﬁcity, or been
practical for use in the ﬁeld.
cThis test was developed and evaluated, but it was not commercialised and is not in use.
dThe Loa Antibody Rapid Test is for Research Use Only (RUO), and is indicated mainly for epidemiological and not diagnostic purposes.
ePoint-of-care tests (POCTs) that can detect biomarkers of active onchocerciasis infection are not yet available, but several promising biomarkers are being evaluated.
fThere are no POCTs for detecting biomarkers of current infection with loiasis; however, there are potential biomarkers under review.
Abbreviations: ICT, immunochromatographic card test; RDT, rapid diagnostic test; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction.International, Inc. Filaria DetectTM anti-Wb123 human IgG4 ELISA, and a rapid diagnostic
test (RDT), the Standard Diagnostics (SD) BIOLINE lymphatic ﬁlariasis IgG4 test (Wb123), for
detection of antibodies speciﬁc to W. bancrofti. In addition, a biplex antibody-based RDT, SD
BIOLINE Oncho/LF IgG4 biplex rapid test, has been developed to detect IgG4 antibodies698 Trends in Parasitology, August 2018, Vol. 34, No. 8
against both W. bancrofti and O. volvulus speciﬁc antigens Wb123 and Ov-16, respectively
[44]. More recently, a multiplex bead platform for antibody detection to species of malaria and
LF has been trialled [45].
What’s New in LF Clinical Disease Classiﬁcation
New developments related to LF clinical manifestations include identifying lymphoedema and
hydocoele, and the simpliﬁcation of the lymphoedema classiﬁcation from seven to three stages
[46,47] for large-scale community-based cases estimates and morbidity mapping [48,49]. In
addition, a new clinical algorithm has been used to help differentiate LF from podoconiosis
lymphoedema in coendemic communities [50]. In terms of measuring and monitoring the
impact of interventions, two new tools have been developed and trialled. The ﬁrst is a novel
portable 3D imaging system to measure limbs in people affected by ﬁlarial lymphoedema [51],
and the second a hand-held tissue tonometer used to assess the compressibility, compare
differences between stages, and monitor the progression of lymphoedema [52,53].
Onchocerciasis
The primary indicators have included skin snip microscopy, involving the examination of a skin
biopsy for direct diagnosis of microﬁlaridermia using a light microscope, and the DEC Patch test
[54], which involves the topical application of DEC to provoke a localized Mazzotti reaction and
indirect diagnosis of Onchocerca microﬁlaridermia. However, skin snips have low sensitivity in
areas with low infection intensity [55], and for several months following ivermectin treatment
when microﬁlaridermia has been reduced or cleared. Furthermore, skin snipping is painful and
has been rejected by entire communities [55,56]. DEC patch tests are less invasive and may be
more acceptable to communities, but the sensitivity has been variable, and will likely also
decrease following MDA. Secondary clinical indicators and tools include examination of the skin
to identify pruritic and atrophic skin lesions, and of the eyes to identify mf in the anterior
chamber of the eye by slit lamp. The examination of onchocercal nodules has been used to
estimate infection prevalence in villages for mapping purposes, and involves palpating a
proportion of adult men to determine the level of onchocerciasis endemicity, that is, Rapid
Epidemiological Mapping of Onchocerciasis (REMO) [57]. Nodule palpation is not suitable for
diagnosis due to the presence of deeper and impalpable nodules that may be missed, and the
potential for misclassiﬁcation of lumps and bumps that resemble nodules [58]. Ultrasound of
nodules can also be used to visualize adult O. volvulus worms, and has been used to conﬁrm
infection or monitor treatment efﬁcacy in clinical studies [59,60]. However, this technique has
several limitations and is not used in onchocerciasis elimination programmes. Immunological
indicators include the anti-Ov-16 ELISA for detecting IgG4 antibodies to the recombinant
antigen Ov-16, which can detect exposure to O. volvulus and infection during the prepatent
period, but cannot distinguish between current infection and historic exposure to the parasite.
Molecular indicators include PCR for the detection of the O. volvulus O-150 tandem repeat
DNA sequence to identify the presence of O. volvulus DNA in skin [61–63], and for xenomo-
nitoring of the black ﬂy vector population [64]. Entomological evaluation by O-150 PCR aims to
determine the prevalence of the infective-L3 stage larvae by pool-screening hundreds of black
ﬂy heads using an O. volvulus-speciﬁc O-150 DNA probe [65].
What’s New in Diagnostic Tests
The most recent developments related to onchocerciasis transmission include a pre-prepared
version of the DEC patch, the LTS-2 Patch [66] and the new RDT and biplex RDT for antibody
detection [67,68]. The LTS-2 Patch has been trialed in a small Phase 2 trial that assessed the
safety, tolerability, and ability to induce Mazzotti reactions, but requires further validation in
larger studies with evaluation of the test’s sensitivity and speciﬁcity. The SD BiolineTrends in Parasitology, August 2018, Vol. 34, No. 8 699
Onchocerciasis IgG4 rapid test is an extension of the Ov-16 ELISA, and uses the recombinant
antigen Ov-16 to detect IgG4 antibodies to the parasite. The SD BIOLINE Oncho/LF IgG4
biplex rapid test detects IgG4 antibodies against both O. volvulus and W. bancrofti antigens
[44]. However the role of the new Ov-16-based IgG4 RDT is yet to be validated for ﬁeld use as
preliminary ﬁeld studies have indicated that it performed well in hyper- and meso-endemic
areas but not in hypo-endemic areas. There are currently no immunoassays commercially
available that can detect O. volvulus antigens (signifying current infection); however, new
biomarkers which can detect subnanogram levels of circulating antigen in O. volvulus-infected
individuals and may provide a platform to detect low-level infections during surveillance in the
future [68].
Loiasis
The primary indicators and diagnostics for loiasis include parasitological identiﬁcation of mf in
day blood smears to identify microﬁlaraemia using light microscopy [69]. Secondary clinical
indicators include the examination of the skin, for Calabar swellings, and the eyes to identify the
adult worm, which has also been used to estimate village prevalence for mapping purposes,
that is, Rapid Assessment Procedure for Loiasis (RAPLOA) using a noninvasive method
involving the questioning of an individual’s eye worm history [70].
What’s New in Diagnostic Tests
The most recent developments related to loiasis transmission include the LoaScope, which
involves the examination of a blood smear for microﬁlaraemia using an adapted iPhone with
image analysis software to quantify the number of mf/ml of blood inserted into a magnifying
device. This new method is part of a new ‘Test and (not) Treat’ (TaNT) Strategy for onchocer-
ciasis elimination, which excludes high-risk individuals from treatment [71,72]. A new immu-
nological indicator for L. loa infection includes the Loa Antibody Rapid Test by Drugs &
Diagnostics for Tropical Diseases, which adapts the recombinant antigen Ll-SXP-1 to a
lateral-ﬂow assay (LFA) platform [73]. This Loa Antibody Rapid Test is currently for research
purposes and has an optional smartphone reader to quantify the line intensity and record GPS
coordinates useful for mapping. Other diagnostic tools developed include molecular assays for
loop-mediated isothermal ampliﬁcation (LAMP) and qPCR, and the identiﬁcation of L. loa-
speciﬁc biomarkers; however, they are not yet POCT [74–76].
Systematic Collection of Data: Standardised Guidelines and Data
Connectivity
Standardised Guidelines
To meet the GPELF and new onchocerciasis elimination targets it is essential that there are
standardised guidelines, which enable endemic countries to systematically collect measures
that are comparable within and between populations over time. The WHO guidelines, reports,
and manuals for LF and onchocerciasis provide a framework for ﬁeld sampling, target pop-
ulations, thresholds and tools. The most recent guidelines for LF (2017) [77] and onchocerciasis
(2016) [21] were approved by the WHO Guideline Review Committee (GRC), an internal
regulatory body responsible for ensuring that WHO guidelines meet the highest international
standards and disseminate recommendations that are trustworthy [78]. See Box 1 for the most
recent publications.
For LF
The new WHO guidelines recommend different approaches for the mapping, monitoring, and
post-MDA surveillance phases, which are summarised in Table 1 [79], and considered key
components of the new Dossier template that will help countries achieve validation of LF700 Trends in Parasitology, August 2018, Vol. 34, No. 8
Box 1. WHO Guidelines, Reports, Manuals Related to Lymphatic Filariasis (LF) and Onchocerciasis
Surveillance and Elimination
Lymphatic ﬁlariasis
2011. Lymphatic ﬁlariasis: monitoring and epidemiological assessment of mass drug administration: a manual for
national elimination programmes. WHO/HTM/NTD/PCT/2011.4
2012. Integrated vector management to control malaria and lymphatic ﬁlariasis – WHO position statement. WHO/HTM/
NTD/2011.2
2013. Lymphatic ﬁlariasis: managing morbidity and preventing disability: an aide-mémoire for national programmes
managers. WHO/HTM/NTD/PCT/2013.7
2013. Lymphatic ﬁlariasis: a handbook of practical entomology for national lymphatic ﬁlariasis elimination programmes.
WHO/HTM/NTD/PCT/2013.10
2016. Strengthening the assessment of lymphatic ﬁlariasis transmission and documenting the achievement of elimina-
tion: WHO/HTM/NTD/PCT/2016.9
2016. Responding to failed transmission assessment surveys WHO/HTM/NTD/PCT/2016.10
2017. Validation of elimination of lymphatic ﬁlariasis as a public health problem. WHO/HTM/NTD/PCT/2017.1
2017. Guideline: alternative mass drug administration regimens to eliminate lymphatic ﬁlariasis WHO/HTM/NTD/PCT/
2017.07
Onchocerciasis
2015. Strategic options and alternative treatment strategies for accelerating onchocerciasis elimination in Africa. WHO/
MG/15.20
2015. Guide for decision making and implementation of vector control as alternative treatment strategies for elimination
of onchocerciasis. WHO/MG/15.22
2016: Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and
procedures. WHO/HTM/NTD/PCT/2016.1
Filariasis coendemicity
2012. Provisional strategy for interrupting lymphatic ﬁlariasis transmission in loiasis-endemic countries. WHO/HTM/
NTD/PCT/2012.6
2016. Integrating national programmes to eliminate lymphatic ﬁlariasis and onchocerciasis. WHO/HTM/NTD/PCT/
2016.4elimination [80]. Currently, the new FTS is the main diagnostic tool being used to assess the
different phases of transmission. For mapping in LF–loiasis coendemic areas, the antigen test
cross-reactivity problem suggests that the speciﬁcity of the Wb123 or Ov-16/Wb123 tests may
be considered conditional or alternatives that can better discriminate between W. bancrofti and
L. loa infections [36,81].
For post-MDA surveillance, a geographical area or an evaluation unit (EU) is used for the new
transmission assessment survey (TAS). The TAS is a survey tool with LQAS-like critical cut-
off for decision making, which is used to assess if the prevalence is <2% in children aged 6–7
years, and is conducted three times over a period of 5–6 years as TAS1, TAS2, and TAS3 [79].Trends in Parasitology, August 2018, Vol. 34, No. 8 701
Table 1. WHO Recommended Surveillance Strategies for Lymphatic Filariasis (LF) Elimination in Africa
Elimination
phases
Duration/timing Purpose Host WHO
test
Target population Sample size and
thresholds
New test Conditional/potential
alternative test
Mapping Phase Before the start of
MDA
Establish the endemicity
in an area considered to
be possibly endemic and
may require MDA
Human mf or ICT >15 years living in
community for>10 years
50–100 people per site in
two high-risk villages at
least 25 km apart
1% endemicity cut-off
FTS Wb123 RDT (SD
Bioline)
Biplex Wb123/Ov-16
in Loa endemic areas
MDA Phase Over 5–6 years at
baseline, before 4th
MDA round (optional)
and before 6th MDA
round
Monitor trends in
infection; determine
eligibility for stopping
MDA
Human mf or ICT People aged >5 years at
one sentinel and spot-
check site per 1 million
population
300 people in villages
with more than 500
people
FTS Wb123 RDT (SD
Bioline)
Biplex Wb123/Ov-16
in Loa endemic areas
Post-MDA
surveillance
phase
Over 4–6 years with
TAS to be conducted
at 2-yearly intervals –
TAS 1, TAS 2, and
TAS 3
Conﬁrm interruption of
transmission at the end
of MDA
Human ICT Children 6–7 years
selected from census,
systematic if cluster
surveys in schools or
communities
1500 to 3000 children
depending upon
sampling approach
<2%
FTS
Ongoing
surveillance
Regular Detect recurrence of
transmission
Human Mixed population groups –
702
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Additional WHO reports have addressed reasons for TAS failure and to help identify corrective
actions useful for national programmes [82]. However, overall, the TAS methodology is
considered to be a useful survey platform and is increasingly being used to assess other
diseases and strategies concurrently, or low transmission areas in Africa and elsewhere [83–
85].
For LF morbidity, the WHO has developed a manual [86] and list of key indicators within the new
Dossier template, which are required for the validation of elimination of LF as a public health
problem, and will help to strengthen health systems to deliver the minimum package of care: (i)
disease burden – estimates of the number of lymphoedema and hydrocoele patients per IU; (ii)
availability of MMDP services – the number of facilities providing services for IUs with known
patients; and (iii) readiness and quality of MMDP – preferred assessment of at least 10% of
designated facilities [87].
For Onchocerciasis
The recent WHO elimination guidelines outline three phases requiring two different approaches
in human populations and female black ﬂy vectors, summarised in Table 2 [21]. Vector
surveillance by O-150 PCR is recommended for use at the end of treatment (Phase 1) to
demonstrate the interruption of transmission and discontinue MDA, at the end of post-
treatment surveillance (Phase 2) to conﬁrm the interruption of transmission, and regularly
for post-elimination surveillance (Phase 3). Surveillance requires a sample of 6000 ﬂies col-
lected from a transmission zone, where less than 1 in 1000 parous ﬂies (<0.1%) and less than 1
in 2000 ﬂies in total (<0.05%) should carry infective L3 larvae, at the upper bound of the 95%
conﬁdence interval [21].
Human surveillance to detect exposure to O. volvulus and ongoing transmission using the Ov-16
ELISA is recommended at theendofPhase1,andconditionally inPhase 2,whentheresultofblack
ﬂy O-150PCRequals or isnear the threshold, or in thecase of insufﬁcientﬂiesor their absence [88].
A sample of 2000 children <10 years of age from sentinel populations is required, and <0.1% of
children should have positive serology at the upper bound of the 95% conﬁdence interval. The Ov-
16 RDT has the potential to replace the ELISA, but requires further validation in different settings
before it can be used in elimination programmes [89]. Skin snip PCR is also indicated during Phase
1 and 2 foruse insome limited situationswhere thereare a few seropositive children (<10children).
Skin snip microscopy and the DEC-patch test may only be used during Phase 1, and not to
demonstrate interruption of transmission. Skin snips may be used during transition to using Ov-16
serology at this time, where the tests should be used in parallel.
For Loiasis Coendemicity
For LF–loiasis coendemic areas, the WHO published a provisional strategy recommending
biannual albendazole plus vector control, including insecticide treated/long-lasting impreg-
nated bednets (ITNs/LLINs), for the elimination of LF in loiasis-endemic areas [90,91]. A
practical approach for scaling up this alternative strategy has been developed to help national
programmes prepare action plans and start implementation [92].
For onchocerciasis hypo-endemic areas, where the risk of SAEs in people with loiasis is consid-
ered to outweigh the beneﬁts of implementing CDTI, alternative TaNT strategies are recom-
mended. The initial recommendation included using microscopy to identify people with L. loa
microﬁlaraemia at risk of SAEs in order to exclude them from treatment [93]. This has been
extendedto include the use of the new rapid LoaScope, with two possible TaNTapproaches: Loa-
ﬁrst and Oncho-ﬁrst [71,72]. Loa-ﬁrst tests people for L. loa ﬁrst to identify those with high mf levelsTrends in Parasitology, August 2018, Vol. 34, No. 8 703
Table 2. WHO Recommended Surveillance Strategies for Onchocerciasis Elimination in Africa
Elimination
phases
Duration/timing Purpose Host WHO test Target
population
Sample size and
thresholds
New test Conditional test/potential alternative
test
Phase 1
Treatment phase
At least 12–15 years Demonstrate
interruption of
transmission for
purpose of stopping
MDA
Human Ov-16 ELISA Children in
sentinel sites
aged <10 years
Sample 2000
children.
An upper bound of
the 95% conﬁdence
interval (CI) <0.1%
Ov-16 RDT (i) Skin snip microscopy: May only be
used in parallel to Ov-16 serology,
during transition to serological testing
(ii) DEC-patch test: Monitor progress
during treatment
(iii) Skin snip PCR: Indicated for use
where few Ov-16 serologically
positive children (<10) are detected
>0.1% threshold
(iv) LoaScope (TaNT strategy)
Vector O-150 PCR Black ﬂies (pool
screen)
Minimum 6000 ﬂies
An upper bound
95% CI of <0.1%
(<1/1000) in parous
ﬁles and <0.05%
(<1/2000) in all ﬂies
Phase 2
Post-treatment
phase
3–5 years Conﬁrm interruption
of transmission at the
end of the post-
treatment period
Human Ov-16 ELISA Children in
sentinel sites
aged <10 years
– Ov-16
RDT
Skin snip PCR: Indicated for use
where few Ov-16 serologically
positive children (<10) are detected
>0.1% threshold
Phase 3
Post-elimination
surveillance
Regularly until the
no risk of
recrudescence
Conﬁrm elimination
of transmission has
been sustained
Vector O-150 PCR Black ﬂies (pool
screen)
–
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at risk of SAEs, and excludes them from treatment with ivermectin. People infected with high levels
of L. loa can then be tested for infection with O. volvulus, and if positive, can be given an alternative
treatment such as the macroﬁlaricidal drug doxycycline. Oncho-ﬁrst tests people for onchocerci-
asis ﬁrst, and positive individuals can then be tested for L. loa before making decisions on what
treatment can be safely administered, whereas the O. volvulus-negative individuals do not receive
treatment [60,94,95]. However, none of the currently available POCTs for onchocerciasis, such as
skin snips, the DEC patch test, or the Ov-16 RDT, are sensitive enough to completely rule out
infection, particularly in hypo-endemic areas where measures of infection may be very low or
absent [55,89]. Therefore, a caveat to strategies that rely on detecting people with O. volvulus
before providing treatment is that this may result in withholding treatment from people who are
actually positive but test false-negative.
Data Connectivity
In terms of data connectivity, the most recent and signiﬁcant development is the availability of
programmatic and research data via online open-access data portals, which aim to harmonise
data ﬂow into a single repository. Rapid advances in mobile technology have enabled the
expansion of smartphone-based data collection platforms.
Data Portals
There are now many NTD data portals available online – see Box 2. The WHO has increased its
scope and availability of data with the aim of strengthening effective data storage, data
management and sharing, as well as to improve the timeliness and completeness of reporting
through more standardised forms to WHO and NTD partners. Currently the portal with the
largest and most detailed data related to LF, onchocerciasis, and loiasis in Africa is via the
ESPEN. The integrated database provides continental-, national-, and subnational-levelBox 2. Data Portals Related to Lymphatic Filariasis (LF) and Onchocerciasis Surveillance
World Health Organization
Integrated NTD database: http://www.who.int/neglected_diseases/data/ntddatabase/en/
PC Data Portal: http://apps.who.int/gho/cabinet/pc.jsp
PCT databank: http://www.who.int/neglected_diseases/preventive_chemotherapy/databank/en/
Global Health Observatory data repository: http://apps.who.int/gho/data/node.main.A1629?lang=en
Global Health Observatory data: http://www.who.int/gho/neglected_diseases/en/
ESPEN AFRO-NTD Portal: http://espen.afro.who.int/
Other
NTD Map: http://www.ntdmap.org/
Global NTD database: https://www.gntd.org/
Global Atlas of Helminth Infection data: http://www.thiswormyworld.org/data-download
NTD database: https://www.ntddatabase.org/?q=content/welcome
ChEMBL-NTD: https://www.ebi.ac.uk/chemblntd
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information on endemicity, coendemicity, mapping surveys, sentinel sites, TAS, MDA rounds,
and MDA coverage. There are several other data portals with a variety of programmatic and
research-based data available; however, the detail on LF, onchocerciasis, and loiasis in Africa
varies considerably and the extent to which they link with WHO portals and national pro-
grammes is unclear.
mHealth Tools
Rapid developments in mobile technology have enabled the development of smartphone-
based data collection platforms, such as the LINKS system, an Android-, web-based
system [96]. The LINKS system allows the collection of a wide range of data through
the open source project Open Data Kit (ODK), helping to reduce costs, increase speed and
ﬂexibility, and improve data quality. By incorporating the inbuilt GPS component of modern
smartphones, LINKS has also been used to map the prevalence of NTDs in 37 countries,
demonstrate scalability, and speciﬁcally to conduct a large-scale integrated TAS assess-
ment [84].
The mobile health (mHealth) tool ‘MeasureSMS-Morbidity’ has provided a unique platform
for readily reporting morbidity cases in endemic IUs, which is required by the Dossier in order for
National programmes to show they can appropriately plan and deliver the minimum package of
care to those people affected by lymphoedema and hydrocoele [48,49,97,98]. The tool is
innovative as it allows community health workers to use their own phone to send clinical
information in a simple format using short message service (SMS). The data are sent to a server
in-country, which then automatically collates the data via a web browser for analysis. From this,
morbidity maps can be developed and the distribution of interventions monitored by the
National programmes. The tool has been used in more than seven countries covering more
than 30 million people to date.
Analysis and Interpretation: Mapping and Modelling
Mapping
There has been an increase in the use of large-scale multicountry prevalence, environmental
and demographic data to create continental-level risk maps using geo-spatial-statistical
methods. For LF, maps were developed from mf (1224 surveys) and ICT (3519 surveys)
data in the literature, and by using environmental and demographic data and spatiotemporal
models within a Bayesian framework [99]. The predicted mf distribution is shown in Figure 4A.
However, these maps need to be revised with different diagnostic and sampling strategies as
a recent review highlights that there is increasing evidence of low or no LF in high-risk L. loa
areas [100], and surveys using ICT in these areas are likely to be invalid due to the L. loa cross-
reactively problem [35–38]. For onchocerciasis, the ﬁrst precontrol map was developed from
microﬁlarial (737 villages) data collected across 11 OCP countries in West African using
Bayesian geostatistical methods and environmental covariates [101]. Further, estimated
prevalence maps of palpable nodules were developed from REMO survey data collected
across 20 APOC countries (14 473 villages), and by using environmental and demographic
data for model-based geostatistical analysis (Figure 4B) [102]. For loiasis, maps were
developed from RAPLOA survey data collected across 11 countries (4798 villages) with
the geostatistical method of kriging used to produce interpolated prevalence estimates of eye
worm history (Figure 4C), and predictive probability maps of prevalence >40% to highlight
areas at risk of SAEs [70].
Microstratiﬁcation overlap mapping (MOM), is a new concept, ﬁrst used for LF to understand
the coendemicity of ﬁlarial infections and codistribution of effective interventions to deﬁne more706 Trends in Parasitology, August 2018, Vol. 34, No. 8
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Figure 4. Sub-Saharan African Maps of Lymphatic Filariasis, Onchocerciasis, and Loiasis Distribution. LF, lymphatic ﬁlariasis; REMO, Rapid Epide-
miological Mapping of Onchocerciasis; RAPLOA, Rapid Assessment Procedure for Loiasis.precisely where and what strategies may be implemented in L. loa coendemic areas [103,104].
The MOM concept has extended to address the risk of SAEs, hypo-endemic hotspots, and
help develop mapping, treatment, and surveillance strategies [92,105–107]. Integrated micro-
mapping is a further new mapping method, ﬁrst used with REMO and RAPLOA methods to
highlight microepidemiologies [108], and then extended to also include LF clinical indicators
[109,110].
Modelling
The new NTD Modelling Consortium brings together infectious disease modellers from 12
academic institutions and aims to reduce the burden of nine NTDs, including LF and oncho-
cerciasis (https://www.ntdmodelling.org/).
With respect to elimination, robust mathematical models are crucial to enable policy makers to
consider: whether elimination targets are feasible with current and/or acceleration strategies;
whether elimination may be thwarted by systematic nonadherence and/or low coverage, and
which criteria could be used to determine when to safely halt MDA for post-treatment surveil-
lance [111].
For both LF and onchocerciasis, there are well established deterministic models (do not
account for random variation) and stochastic models (do account for random variation). For
LF, these include: EPIFIL (deterministic), LYMFASIM (stochastic), and TRANSFIL (stochastic)
[112,113]. For onchocerciasis these include: EPIONCHO (deterministic) and ONCHOSIM
(stochastic, with a deterministic component) [114].
It is important to recognise that, as well as using different statistical methods to reach their
predictions, each of these models is based on data from different epidemiological settings.
Over time, with increasing knowledge of transmission dynamics in different epidemiological
settings with different interventions, these models have undergone multiple adaptations to
optimise the reliability of their predictions [112].
One innovative adaptation has been to combine three of the key model frameworks together in
a ‘multi-model ensemble’ [113]. Despite intrinsic variance between individual models, theirTrends in Parasitology, August 2018, Vol. 34, No. 8 707
Outstanding Questions
How to better integrate the different
components and tools of surveillance
into a more holistic format?
How to coordinate the surveillance pri-
orities between the diverse range of
partners?
How to maintain updated surveillance
strategies as new diagnostics and
drug regimens are introduced?
How to combine the different elimina-
tion threshold measures between
diseases?
How to introduce high-tech complex
diagnostic tools to the community
level?
How to better use the tools and tech-
nologies currently available on a larger
scale?
How to ensure NTD programme can
access and use the data available to
inform decisions?predictions of intervention impact were more plausible when combined than individually. Tools
to calibrate simulation models have also been developed, for example a ‘Bayesian melding
framework’ which was developed using surveillance data from 22 geographically distinct sites
[115]. Novel models have also been developed, for example a stochastic version of EPIFIL,
without immunity [116].
As loiasis is not currently recognised as an NTD by WHO, mathematical models for neither its
transmission nor control have been developed but have been suggested as a research and
development priority [10]. The main priority for Loa modelling has been in predicting the
distribution of infection intensity: to determine where the greatest risk of SAEs are during
MDA for LF and onchocerciasis [117].
Concluding Remarks
All the new strategies presented in this review will play an essential role in the elimination of LF
and onchocerciasis and need to be considered holistically with better linkages and greater
cross-disease integration. It will be important to ensure that National NTD Programmes have
access to all the available tools, and that there is sufﬁcient national capacity to implement and
contextualise these new tools and methodologies. This will require WHO and other stakeholders
to prioritise the development of the human resources and specialised capacity within countries
to enhance technical knowledge, and importantly, to translate that policy knowledge into
practice as the essential framework for satisfying the achievement of the programmatic goal
of elimination.
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